Phase 1 B-ALL Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca236 enrolled80 locationsNCT06137118
Recruiting
Phase 1Phase 2
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
B-ALLAML/MDST-ALL+1 more
St. Jude Children's Research Hospital108 enrolled2 locationsNCT04318678
Recruiting
Phase 1
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
LeukemiaB-ALL
ImmunityBio, Inc.10 enrolled2 locationsNCT07556757
Recruiting
Phase 1
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
B-ALL
Zhejiang University30 enrolled1 locationNCT07246707
Recruiting
Phase 1Phase 2
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 1Phase 2
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
B-ALL
Chongqing Precision Biotech Co., Ltd40 enrolled1 locationNCT04781634